340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

TogetherRx Access Closes Doors on 2M customers

 

TogetherRx Access, a drug discount card program sponsored by drug companies, is being discontinued as of Feb. 28, 2014. The reason? Big Pharma says participants will get a better deal on prescriptions by getting insured through the Affordable Care Act or Medicaid. “We have determined that individuals and families who need help obtaining their prescription medicines may be … [Read more...]

Big Pharma Profiteering on Orphan Drugs (Part 3)

 

The Seattle Times has published the next installment of its investigation of drug industry profiteering from orphan drugs. It's entitled How a Drug for a Few Patients Was Turned Into $81 Million in Sales. The story describes how Cell Therapeutics Inc. systematically spread the word among physicians (sometimes with the assistance of patient advocacy groups) about potential … [Read more...]

Big Pharma Profiteering on Orphan Drugs (Cont’d.)

 

Earlier this week, we reported that The Seattle Times is investigating drug industry profiteering from orphan drugs. Now, the business news website Quartz has run its own the story on the topic. "There's good reason for big pharma's attraction to rare disease treatments," writer John McDuling says in Forget Viagra: Why Rare Diseases are Big Pharma’s Latest Obsession. "Revenue … [Read more...]

340B Hospitals Face Double Whammy in Many States

 

Recently, we described how the Affordable Care Act (ACA) is squeezing public and private nonprofit hospitals’ finances—making hospitals’ continued access to 340B drug discounts more important than ever. This past Saturday, the front-page lead story in The New York Times took an in-depth look at how two SNHPA member hospitals in Georgia are struggling to cope with ACA's cuts in … [Read more...]

Report: Big Pharma Profiteering on Orphan Drugs

 

The Seattle Times has published the first installment of an investigation of drug industry profiteering from orphan drugs. It's called "Pharma's Windfall: The Mining of Rare Diseases." Orphan drugs are pharmaceuticals approved to treat diseases affecting fewer than 200,000 patients in the United States. The federal government gives drug manufacturers multiple incentives to … [Read more...]

Newest AIR340B Member Nailed for Fraud

 

Johnson & Johnson—which less than a week ago was accused in California of cheating on 340B discounts for AIDS drugs—has just agreed to pay $2.2 billion to settle a slew of civil and criminal claims, mainly over the illegal marketing of its antipsychotic Risperdal and several other medicines. It is one of the largest health care fraud settlements in U.S. history, including … [Read more...]

ACA Expands 340B Eligibility but Also Puts Squeeze on Hospitals

 

Some critics of the 340B drug discount program say it should be phased out because millions of people will get health coverage under health care reform. This argument ignores that other parts of the Affordable Care Act (ACA) are squeezing public and private nonprofit hospitals' finances—making hospitals' continued access to 340B drug discounts more important than … [Read more...]

« Previous Page
Next Page »

LATEST ARTICLES DELIVERED

Get new article alerts via email.

This field is required.

Check your inbox or spam folder now to confirm your subscription.

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS feed: 340B Employed 340B Employed

  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Compliance Analyst Certified | UNC Health November 17, 2026
  • 340B Program Specialist | Vail Health November 17, 2026
  • Pharmacy Manager, 340B Program | Tufts Medical Center November 11, 2026
  • 340B Program Pharmacy Manager | Allies for Health + Wellbeing November 10, 2026

Copyright © 2026 · 340B Health